Paiote: Signs Agreement with AvalonPharma for Commercialization Rights of BAT3306 Injection Solution

Baiotai announcement, the company signed an authorization license and production, supply, and commercialization agreement with Avalon Pharma, granting exclusive commercialization rights of BAT3306 injection in Saudi Arabia and the Middle East and North Africa regions to Avalon. The agreement includes a $2 million upfront payment, cumulative milestone payments not exceeding $5 million, and a two-digit percentage revenue share of net sales. The agreement is valid for fifteen years from the effective date, with the option to renew for two years. This move is expected to have a positive impact on the company's future performance and enhance profitability.